EUVIMEDOpdag EUVIMED
Crossref

A high‐titer scalable Chinese hamster ovary transient expression platform for production of biotherapeutics

Juan C Gonzalez-Rivera, Alberto Galvan, Todd Ryder, Monica Milman, Kitty Agarwal iD, Lakshmi Kandari iD, Anurag Khetan iD

Biotechnology and Bioengineering · 2024

DOI: 10.1002/bit.28817 ↗

At a glance

Journal article in Biotechnology and Bioengineering, 2024. Written by Juan C Gonzalez-Rivera and 6 co-authors. Institution: Biologics Development, Bristol Myers Squibb, New Brunswick, New Jersey, USA. Major MEDLINE topics: Cricetulus, Bioreactors, Antibodies, Monoclonal. Cited 7 times so far (Crossref); 67 references.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Transient gene expression (TGE) in Chinese hamster ovary (CHO) cells offers a route to accelerate biologics development by delivering material weeks to months earlier than what is possible with conventional cell line development. However, low productivity, inconsistent product quality profiles, and scalability challenges have prevented its broader adoption. In this study, we develop a scalable CHO‐based TGE system achieving 1.9 g/L of monoclonal antibody in an unmodified host. We integrated continuous flow‐electroporation and alternate tangential flow (ATF) perfusion to enable an end‐to‐end closed system from N‐1 perfusion to fed‐batch 50‐L bioreactor production. Optimization of both the ATF operation for three‐in‐one application—cell growth, buffer exchange, and cell mass concentration—and the flow‐electroporation process, led to a platform for producing biotherapeutics using transiently transfected cells. We demonstrate scalability up to 50‐L bioreactor, maintaining a titer over 1 g/L. We also show comparable quality between both transiently and stably produced material, and consistency across batches. The results confirm that purity, charge variants and N‐glycan profiles are similar. Our study demonstrates the potential of CHO‐based TGE platforms to accelerate biologics process development timelines and contributes evidence supporting its feasibility for manufacturing early clinical material, aiming to strengthen endorsement for TGE's wider implementation.

Subjects

MeSH terms (MEDLINE)

CricetulusBioreactorsAntibodies, MonoclonalAnimalsCHO CellsCricetinaeRecombinant ProteinsBiological ProductsGene Expression

Author keywords

50‐L bioreactorChinese hamster ovary (CHO) cellsalternating tangential flow (ATF) perfusioncontinuous flow‐electroporationproduct quality attributestransient gene expression

Substances

Antibodies, MonoclonalRecombinant ProteinsBiological Products

Authors and institutions

  • Biologics Development, Bristol Myers Squibb, New Brunswick, New Jersey, USA.

ORCID profiles: Kitty Agarwal, Lakshmi Kandari, Anurag Khetan

Cite

APA

Gonzalez-Rivera, J. C., Galvan, A., Ryder, T., Milman, M., Agarwal, K., Kandari, L., & Khetan, A. (2024). A high‐titer scalable Chinese hamster ovary transient expression platform for production of biotherapeutics. Biotechnology and Bioengineering. https://doi.org/10.1002/bit.28817

Vancouver

Gonzalez-Rivera JC, Galvan A, Ryder T, Milman M, Agarwal K, Kandari L, et al. A high‐titer scalable Chinese hamster ovary transient expression platform for production of biotherapeutics. Biotechnology and Bioengineering. 2024. doi:10.1002/bit.28817

BibTeX
@article{GonzalezRivera2024,
  author = {Gonzalez-Rivera, Juan C and Galvan, Alberto and Ryder, Todd and Milman, Monica and Agarwal, Kitty and Kandari, Lakshmi and Khetan, Anurag},
  title = {A high‐titer scalable Chinese hamster ovary transient expression platform for production of biotherapeutics},
  journal = {Biotechnology and Bioengineering},
  year = {2024},
  doi = {10.1002/bit.28817}
}
Start for free →